(S) -3-Hydroxypyrrolidinum Hydrochloridum CAS 122536-94-1 Puritas ≥98.0% (GC) Darifenacin Hydrobromidum Intermedium

Description:

Nomen chemicum: (S)-3-Hydroxypyrrolidinum Hydrochloridum

CAS: 122536-94-1

Aspectus: Off-White ad Brown Crystallinum Pulvis

Puritas: ≥98.0% (GC)

Medium Hydrobromidis de Darifenacin (CAS 133099-07-7) in curatione vesicae Overactive

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Manufacturer cum princeps munditiae et auctor pretium
Commercial Supple Darifenacin Hydrobromide Related Intermedia:
(S) -3-Hydroxypyrrolidinum Hydrochloridum CAS: 122536-94-1
(S)-α, α-Diphenyl-3-Pyrrolidineacetamide L-Tartrate CAS: 134002-26-9
Hydrobromide CAS: 194602-27-2
(S)-2,2-Diphenyl-2-(1-Tosylpyrrolidin-3-yl) acetotrile CAS: 133099-09-9
2,3-Dihydrobenzofuran CAS: 496-16-2
2,3-Dihydrobenzofuranyl-5-Acidum aceticum CAS: 69999-16-2
5-(2-Bromoethyl)-2,3-Dihydrobenzofuran CAS: 127264-146
Darifenacin Hydrobromide CAS: 133099-07-7

Chemical Properties:

Nomen chemicum (S) -3-Hydroxypyrrolidine Hydrochloride
Synonyma (S) -3-Hydroxypyrrolidine HCl;(S) -3-Pyrrolidinol Hydrochloride;(S) -Pyrrolidin-3-ol (Hydrochloride);(S) -Pyrrolidin-3-ol, HCl
CAS Number 122536-94-1
CATTUS Number RF-CC103
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C4H10ClNO
M. Pondus 123.581
Liquescens punctum 104°C ad 107°C
Ferveret 108°C ad 110°C (8mmHg)
Solubilitas DMSO (parce), Methanol (Pariter)
Shipping Condition Uit sub Ambient Temperature
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Off-White ad Brown Crystalline pulveris
Puritas chemica ≥98.0% (GC)
Imprimis Rotationes +6.5° ~ +8.5° (C=3 CH3OH)
Omnis immunditia ≤0.50%
Totalis immunditias ≤2.0%
Damnum in Siccatio ≤0.50%
Residere in Ignition ≤0.50%
Test Standard Enterprise Standard
Consuetudinem Darifenacin Hydrobromida (CAS: 133099-07-7) Intermedia

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?
Please contact: sales@ruifuchem.com 

QA (Quality Assurance)?
Certa qualitas certitudinis, stricte procuratio.Instrumentum professionalem ad analysin includunt NMR, LC-MS, GC-MS, HPLC, UPCC/HPLC, GC-HS, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Modus test Microbialium. , etc.

Free Exempla?
Free exemplaria pro qualitate aestimatio available.

Factory Audit?
Factory audit gratissimum.Quaeso ante constitutum.

MOQ?
Nec MOQ. Parvus ordo placet.

Tempus adferendi?
Si intra stirpem, tres dies partus praestatur

Transportatio?
Per Express (FedEx, DHL), per Air, per mare.

Consuetudo Synthesis?
Consuetudo potest providere officia synthesin.

Pensio conditio?
T/T (translatio telex), Nordea, Unio occidentalis, etc.

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est praecipuum fabricam et supplementum (S)-3-hydroxypyrrolidinis hydrochloridis (CAS: 122536-94-1) cum qualitate alta, in synthesi organica late adhibita, synthesis intermediorum pharmaceuticae et pharmaceuticae Ingredientis activae. (API) synthesis.(S) -3-Hydroxypyrrolidinum hydrochloridum (CAS: 122536-94-1) principale medium est Hydrobromidis Darifenacin (CAS: 133099-07-7).

Darifenacin hydrobromida (CAS: 133099-07-7), viva voce, semel in die receptor selectivus M3, immissus est ad curationem vesicae nimiae in patientibus cum indicia urgentis urinae incontinentiae, necessitatis et frequentiae.Medicamentum selective inhibet receptorem M3 in musculo detrusore, dum receptoribus M1 et M2 parcit, qui in systemate nervoso centrali et munere respective cardiovasculari involvi creduntur.Compositum a Pfizer principio enucleatum et licentiatum Novartis et Bayer fuit.

Epistulam tuam hic scribe et mitte nobis